I thank the gentleman for yielding. In the early days of my medical practice in the 1980s, I would sit around with other doctors and kvetch that there were treatments available in Europe that were not available in the United States. But…
Michael Burgess
The Public Record
Michael Clifton Burgess is an American politician and physician who has served as the U.S. Representative for Texas's 26th congressional district since 2003. A member of the Republican Party, Burgess has focused on healthcare policy, leveraging his medical background to inform his legislative work. He has been involved in various committees and has advocated for issues such as medical research and veterans' healthcare. Burgess has also been a vocal supporter of conservative fiscal policies and has participated in discussions surrounding healthcare reform.
H. Res. 750 expresses the sense of Congress that individual choice in health insurance should be protected. Almost 160 million Americans under 65 years of age are enrolled in employer- sponsored health insurance, and another 14 million…
I'm not sure the Three Wise Men would appreciate your comparison, as this North Star journey would lead our healthcare system as we currently know it to disintegrate into ashes.
Single-payer healthcare would be another failed attempt at a one-size-fits-all approach to healthcare.
We simply cannot afford the financial or human suffering that would accompany such a misguided policy.
Medicare for All would eliminate private insurance, employer-sponsored health insurance, Medicaid, the Children's Health Insurance Program upon which many Americans depend.
I introduced HR 1510, the Premium Relief Act of 2019, which includes reinsurance that is coupled with a structural reform of the Affordable Care Act.
More than 70 percent of Americans are satisfied with their employer-sponsored insurance, which does provide robust protections.
It is clear that a socialist takeover of even one sector of the healthcare industry--prescription drugs--in Speaker Pelosi's HR 3, there would be a reduced number of new drugs coming to market.





